In the era of molecularly targeted agents (MTAs), it is recommended to account for toxicity over several cycles to identify the recommended phase II dose (RP2D). We investigated the relationship between the risk of toxicity at cycle 1 and the cumulative incidence of toxicity over subsequent cycles in trials of single MTAs.

中文翻译：

---

靶向治疗的累积毒性：在推荐的II期剂量下可以期待什么。

在分子靶向药物（MTA）时代，建议考虑多个周期的毒性以确定推荐的II期剂量（RP2D）。在单个MTA试验中，我们研究了第1周期中毒性风险与后续各周期中毒性累积发生率之间的关系。